Form 4: Synaptogenix Director Acquires Stock Options

Bruce Bernstein, a director of Synaptogenix, Inc., acquired stock options exercisable for 800 shares of common stock.

Summary

• On April 3, 2025, Bruce Bernstein, a director of Synaptogenix, Inc., acquired stock options.
• The options are exercisable for 800 shares of common stock at a price of $2.28 per share.
• The options vest after one year of service from April 3, 2025, and expire on April 3, 2035.
• Following the transaction, Bernstein directly owns 800 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative sentiment, but rather a routine transaction.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule implies continued service by the director.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a change in beneficial ownership by a company director, which is common.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as a form of compensation and incentive.
• The vesting schedule of one year is fairly standard.
• The specific terms of the option grant (exercise price, number of shares) would need to be compared to similar companies in the biotechnology industry to assess its competitiveness.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates

Keywords

Synaptogenix, Director, Stock Options, Beneficial Ownership, Form 4, SNPX, Securities